Intellia pauses late-stage trials of gene-editing treatment after serious liver event
27/10/2025 11:37
Oct 27 (Reuters) - Intellia Therapeutics NTLA.O said on Monday it has temporarily stopped dosing and screening patients in two late-stage studies of its one-time gene-editing treatment for a heart condition after a patient experienced a serious liver problem. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shailesh Kuber) ((Padmanabhan.Ananthan@thomsonreuters.com;))
Recent news on INTELLIA THERAPEUTICS
See all newsU.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Intellia rises after FDA grants fast-track status to its treatment for rare disease
Brief: Intellia Therapeutics Announces FDA Acceptance Of Biologics License Application With Priority Review For Lonvoguran Ziclumeran (Lonvo-Z) For Hereditary Angioedema (Hae)